Telehealth Hospice Visits for Breast Cancer

Overseen by Claire Smith, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: Dana-Farber Cancer Institute

No Placebo Group

Trial Summary

What is the purpose of this trial?

The aim of this research study is to better understand the in-home hospice experience for participants, caregivers, hospice nurses, and oncology providers by conducting telehealth check-ins between participants and caregivers and oncology care teams.

Research Team

Claire Smith, MD

Principal Investigator

Dana-Farber Cancer Institute

Eligibility Criteria

The COMPASSION Study is for individuals with breast cancer who are currently receiving in-home hospice care. It's designed to understand the experience of patients, caregivers, and healthcare providers by using telehealth check-ins.

Inclusion Criteria

I can speak and agree to take a survey in 4-6 weeks if I'm well enough.

Hospice setting is within Massachusetts

I need an interpreter for my appointments, which will be arranged.

Exclusion Criteria

Hospice setting outside of Massachusetts

I am 18 years old or older.

I started in home hospice care and may move to inpatient hospice.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

1 week

1 visit (phone call)

Introduction and Consent

Introduction to study and survey by brief, verbal consent via phone call

1 week

1 visit (phone call)

Survey and Check-ins

Participants complete a survey and have 4 weekly check-ins via Zoom or phone call with the study team

4-6 weeks

4 visits (virtual)

Follow-up

Participants are monitored for completion of telehealth intervention

4 weeks

Treatment Details

Interventions

• Telehealth Hospice Visits (Behavioural Intervention)

Trial Overview This study tests the effectiveness of telehealth visits as a way to support people with breast cancer and their caregivers during in-home hospice care, involving regular virtual interactions with oncology teams.

Participant Groups

Group I: Compassion Cohort Experimental Treatment 1 Intervention

25 participants will complete study procedures as follows: * Introduction to study and survey by brief, verbal consent via phone call. * At 4-6 weeks: survey completion via email or phone. * 4 weekly check-ins via Zoom or phone call with study team.

Group II: Usual Care Cohort Active Control 1 Intervention

25 participants will complete study procedures as follows: * Introduction to study and survey by brief, verbal consent via phone call. * At 4-6 weeks: survey completion via email or phone.

Who Is Running the Clinical Trial?

Dana-Farber Cancer Institute

Lead Sponsor

Trials

1,128

Recruited

382,000+

Dr. Benjamin L. Ebert

Dana-Farber Cancer Institute

Chief Executive Officer

MD from Harvard Medical School, PhD from Oxford University

Dr. Craig A. Bunnell

Dana-Farber Cancer Institute

Chief Medical Officer since 2012

MD from Harvard Medical School, MPH from Harvard School of Public Health, MBA from MIT Sloan School of Management